Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 1/20 | 0.43 |
| ▸ | CD40LG | P29965 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705734 | 0.86 | ALDH1A1 (0.45) | CD40CD40LGALDH1A1KDM4EMAPT | |
| SCHEMBL7537324 | 0.85 | HDAC6 (0.50) | CD40CD40LG | |
| SCHEMBL7987999 | 0.83 | ALDH1A1 (0.43) | CD40CD40LGALDH1A1KDM4EMAPT | |
| SCHEMBL6223758 | 0.83 | CD40 (0.39) | CD40CD40LGALDH1A1KDM4EMAPT | |
| SCHEMBL10584547 | 0.82 | FLT3 (0.51) | KDM4E | |
| SCHEMBL446291 | 0.81 | MMP2 (0.42) | CD40CD40LGCYP1A2MAPK1 | |
| SCHEMBL13753754 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL8692390 | 0.81 | CD40 (0.40) | CD40CD40LGJAK2JAK1 | |
| SCHEMBL22099898 | 0.80 | MAPT (0.53) | CD40CD40LGMAPTLMNAPOLB | |
| SCHEMBL7978406 | 0.80 | B3GNT2 (0.44) | CD40CD40LGALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025211-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | Trevena, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| WO-2021046183-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | CD40 4229/4885CD40LG 4467/4885ALDH1A1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.